Drug Profile
Latanoprost controlled release - Peregrine Ophthalmic
Alternative Names: Latanoprost extended release -Preregrine Ophthalmic; Latanoprost liposomal - Peregrine Ophthalmic; LIPOLAT; liposomal latanoprost - Peregrine Ophthalmic; POLAT 001Latest Information Update: 11 Jul 2023
Price :
$50
*
At a glance
- Originator Peregrine Ophthalmic
- Class Antiglaucomas; Prostaglandins; Small molecules
- Mechanism of Action Prostaglandin F2 alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Glaucoma; Ocular hypertension
- Phase I Subcutaneous fat disorders
Most Recent Events
- 28 Apr 2023 Phase-I clinical trials in Subcutaneous fat disorders (In volunteers) in USA (Transdermal) (NCT05935527)
- 02 Jan 2023 No development reported - Phase-II for Subcutaneous fat disorders (In adults) in Thailand (Transdermal)
- 25 Nov 2020 Phase-II clinical trials in Subcutaneous fat disorders (In adults) in Thailand (Transdermal, Injection) (Peregrine Ophhalmic website, November 2020)